FDA Brief

Warning letters Drugs

FDA warning letter to

Apothecary Pharma, LLC

High riskIssued Dec 1, 2025Posted Mar 17Center for Drug Evaluation and Research (CDER)

FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

What happened

FDA inspected Apothecary Pharma's outsourcing facility—a compounder registered to make sterile drugs—from May 12 to May 15, 2025, and issued a Form 483 listing inspection findings. Investigators found sterile drug products made under insanitary conditions that could contaminate them, plus current good manufacturing practice (CGMP) failures. FDA also found some labels missing required ingredient and use information and adverse event reporting procedures inadequate.

What FDA found

  1. Sterile drug products were prepared under insanitary conditions, including blocked sterile airflow, arms resting in the hood, unsanitized gloves, exposed skin, inadequate smoke studies, and rusty or hard-to-clean equipment.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The company did not establish or follow written responsibilities and procedures for its quality control unit.

    21 CFR 211.22(d)
  3. The company did not establish and follow adequate written procedures to prevent microbial contamination, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  4. The company did not ensure manufacturing personnel wore clothing appropriate to protect the drug product from contamination.

    21 CFR 211.28(a)
  5. The company lacked adequate systems for maintaining equipment used to control aseptic conditions and for cleaning and disinfecting the room and equipment.

    21 CFR 211.42(c)(10)(v), (vi)
  6. Labels for Tirzepatide Injection 10 mg/mL and Semaglutide Injection 2.5 mg/mL lacked a list of active and inactive ingredients, and some containers lacked adverse event reporting information and directions for use.

    FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]

What FDA wants

Within 15 working days, Apothecary Pharma must notify FDA in writing of the specific steps it has taken to address the violations, prevent recurrence, and include supporting documents; if it cannot complete the work, it must explain the delay and when it will finish. FDA also strongly recommends a comprehensive assessment of operations with a third-party consultant who has sterile drug manufacturing expertise.

Who should pay attention

  • health systems and clinics that buy compounded sterile drugs
  • compounding pharmacies and outsourcing facilities making sterile products
  • providers or brands using compounded tirzepatide or semaglutide

This is a summary. Read the original letter on fda.gov.

Apothecary Pharma, LLC's FDA history

Recalls in the last 12 months

Oct 14 Class II Apothecary Pharma LLC
Drug
Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18.
Lack of Assurance of Sterility
Oct 14 Class II Apothecary Pharma LLC
Drug
Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vial, Rx Only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC, 27513, NDC 85091-011-06.
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk